ESMO Congress 2023 – Presentation
Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Demonstrates Clinical Activity in Recurrent Epithelial Endometrial Cancer: STRO-002-GM1 Phase 1 Dose Expansion
Luveltamab Tazevibulin (STRO-002), an Anti-Folate Receptor Alpha Antibody Drug Conjugate, Demonstrates Clinical Activity in Recurrent Epithelial Endometrial Cancer: STRO-002-GM1 Phase 1 Dose Expansion